The aim of this analysis was to evaluate the safety and activity of cabozantinib in a large unselected population of patients with metastatic renal-cell carcinoma (mRCC) progressing after prior treatments. Our data showed that cabozantinib is effective in a large unselected population of mRCC patients treated in everyday clinical practice. Cabozantinib was also safe and its toxicity profile was feasible and manageable. Background: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. Methods: Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between September and December 2016. Patients with mRCC with disease that progressed after one or more prior systemic treatment were evaluated. Cabozantinib 60 mg was administered orally once daily. Doses were reduced to 40 mg or 20 mg in patients experiencing grade 3 or intolerable grade 2 adverse events (AEs). Results: Data from 96 patients were evaluated. Cabozantinib was administered as second-line therapy in 28 patients
Introduction
Renal-cell carcinoma (RCC) represents the seventh most common cancer, with 330,000 cases diagnosed and more than 140,000 deaths per year worldwide. 1 Tumor angiogenesis represents a major hallmark in RCC initiation and progression. Previous studies have demonstrated that the Von HippeleLindau protein is frequently down-regulated, leading to stabilization of the hypoxia-inducible factors a and b, and upregulation of several genes including vascular endothelial growth factor (VEGF ), mesenchymaleepithelial transition factor (MET ), and AXL. 2, 3 These alterations provide the rationale for the angiogenic drive of clear-cell RCC and expression of MET or AXL have been associated with an invasive tumor phenotype and poor prognosis. [3] [4] [5] [6] Over the last decade, several agents such as the tyrosine kinase inhibitors (TKIs) directed against angiogenic drivers of metastatic RCC (mRCC) were introduced in clinical practice. By targeting endothelial cell proliferation, tumor angiogenesis, and growth, these compounds have revolutionized the treatment of mRCC patients, resulting in a significant increase in progression-free survival (PFS) and overall survival (OS). 7, 8 Cabozantinib (XL-184) is an oral multiple TKI with activity against several kinases including VEGF receptor (VEGFR-2), MET, RET (REarranged during Transfection), KIT, AXL, TIE2 (endothelial-specific receptor tyrosine kinase 2) and FLT3 (Fms-like tyrosine kinase). 9 In phase 1 and 2 studies, cabozantinib demonstrated good tolerability and significant antitumor efficacy in mRCC patients. 10, 11 On the basis of these data, a phase 3, randomized, open-label trial comparing cabozantinib with everolimus in mRCC patients with disease that progressed after VEGFR-TKI therapies (METEOR study) was conducted. 12, 13 In this study, 658 patients were enrolled, with PFS as the primary end point. OS and overall response rate (ORR) were also evaluated as key secondary end points. The METEOR trial showed a median PFS of 7. The aim of this analysis was to evaluate the safety and activity of cabozantinib in a large unselected population of patients with mRCC that progressed after prior treatments.
Methods

Managed Access Program
Early access refers to the possibility of using a medicinal product not yet approved or commercially available for patients with a severe disease for which no therapeutic alternative is available, and for whom enrollment in a clinical trial is not possible. A number of different terms are used around the world to describe early access. Article 5(1) of Directive 2001/83/EC provides a legal basis to the EU member states to supply unauthorized medicines in response to unsolicited requests for nominative individual patients. Eligible patients based on the EU indication benefited from early access to cabozantinib in Italy under the physician's responsibility. 15 
Study Population
Data were collected from 24 Italian cancer centers where a cabozantinib managed access program (MAP) was available, upon physician request, between September and December 2016. Eligible patients were aged 18 or older, had advanced or mRCC with both clear and noneclear-cell histology, and had disease with measurable lesions including brain metastases. Patients must have received at least one prior anticancer therapy for metastatic disease, which could include TKIs and monoclonal antibodies (including those targeting VEGF) and immune-checkpoint inhibitors of the programmed death 1 (PD-1) receptor or its ligand, PD-L1. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 and an interval of at least 28 days since completion of the previous treatment. Informed consent was signed at the beginning of the treatment.
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Cabozantinib in mRCC Treatment
Cabozantinib was provided orally 60 mg once daily on 28-day cycles. Although not specified in the MAP, a reduced starting dose of 40 mg was prescribed to patients with worse clinical conditions, with a dose escalation to 60 mg if treatment was well tolerated. Treatment modifications, including interruptions and dose reductions, were allowed to manage adverse events (AEs). Cabozantinib treatment was resumed at a lower dose as follows: from 60 mg to 40 mg, and from 40 mg to 20 mg.
Response and Tolerability End Points
Efficacy and tolerability outcomes were retrospectively assessed. For the current analysis, PFS was defined as the interval between the date of treatment start and the first documentation of radiologic and clinical PD or death by any cause. Other efficacy end points were OS and ORR. Tumor response or progression was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 16 Safety of treatment was monitored by the investigator, and AEs were assessed with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
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Statistical Analysis
Patient and disease characteristics were analyzed using descriptive statistics. Discrete variables were expressed as relative frequencies and continuous variables as median and range. The median survival was estimated by the Kaplan-Meier method, and survival between different groups was compared by the log-rank test. 
Results
Data from 96 patients who initiated treatment with cabozantinib from September to December 2016 within the MAP were collected. Patient characteristics are listed in Table 1 . Most patients were male with a median age of 65 years (range, 41-84 years), ECOG PS 1, intermediate risk as per Heng prognostic score, and 3 or more different metastatic sites of disease. Cabozantinib was provided as second-line therapy in 28 patients (29%), as third-line therapy in 18 patients (19%), and as a further line of therapy in the remaining 50 patients (52%). None of the patients had received cabozantinib without a prior anti-VEGF therapy. Sixty-six patients (69%) initiated treatment with the full dose of 60 mg. Because of poor clinical conditions, 29 patients (30%) initiated treatment at a reduced dose of 40 mg daily and only one at 20 mg daily. Only 2 patients in this group received an increase to the full dose after showing good tolerability to the treatment.
At the time of our analysis, the median PFS was 8.0 months (range, 0.5-10.8 months); median OS was not reached, with 1-year OS of 65% (Figure 1 ). Tumor response assessment is shown in Figure 2 . Partial response to treatment, radiologically assessed according to the RECIST v.1.1 criteria, was observed in 35 patients (36%), while stable disease was observed in 33 patients (34%). None of the 96 patients experienced a complete response. The remaining 28 patients (30%) experienced PD. In those patients with disease with partial response or with stable disease, the median duration of response was 6 months. Univariate analysis of PFS and OS (Figures 2 and 3) did not show any significant predictors of survival, with the exception of treatment line. Indeed, patients who initiated cabozantinib therapy after 3 or more lines had a decreased risk of progression (P ¼ .0062) and death (P ¼ .014). Moreover, in terms of drug efficacy, the initial dose of cabozantinib of 60 mg Figure 3 ). The median duration of treatment was 7.4 months. Dose was reduced because of AEs in 40 patients (42%), and most of them (27%) reduced from a starting dose of 60 mg to 40 mg. Only 5 patients (5%) discontinued treatment because of AEs. The AEs leading to a dose discontinuation were pulmonary embolism, severe gastrointestinal bleeding, diarrhea, and fatigue. All AEs reported during treatment are listed in Table 2 . The incidence of any grade AEs in patients treated within the MAP was 94%, with an overall incidence of grade 3/4 AEs of 36%. The most common grade 3/4 AEs with cabozantinib were diarrhea (7%), asthenia (7%), and hypertension (5%); the most frequently observed any-grade AEs were asthenia (42%), diarrhea (38%), handefoot syndrome (30%), mucositis (26%), nausea (21%), and hypertension (21%). At a lower frequency, hypothyroidism, gastrointestinal and cutaneous toxicity, bleeding, and pneumonia were reported. The AEs leading to a dose reduction were pulmonary embolism, severe gastrointestinal bleeding, diarrhea, and fatigue. No grade 5 AEs were observed. Deaths due to any cause occurred in 32 patients (33%), and were all related to PD.
Discussion
In this retrospective study, we analyzed for the first time the efficacy and safety of cabozantinib in the everyday clinical practice setting. Median PFS observed in patients treated with cabozantinib in the MAP was 8.03 months, with an ORR of 36%. Although not directly comparable because of differences between patient populations, these efficacy data confirmed what was previously reported in patients treated within clinical trials. In the phase 3 METEOR study, 12,13 a median PFS of 7.4 months was observed with an ORR of 17%, comparable to that reported in our analysis. Our analysis showed that cabozantinib was active irrespective of the administered dose, and no significant difference in terms of PFS and OS was observed among patients treated with a dose of 60 mg and those treated with 40 mg, but also in patients who reduced the dose because of AEs and those who continued treatment without any dose reduction. At univariate analysis, the only prognostic factor that was significantly associated with clinical outcome was the number of previous lines of treatment received, in particular 3 or more lines (PFS, P ¼ .0062; OS, P ¼ .75). These data were confirmed at multivariable analysis. These results make sense considering that RCC is a heterogeneous disease, and the disease of a subgroup of patients with mRCC shows an indolent course over the years, thus allowing patients to receive multiple lines of treatment. The prolonged survival of such patients observed in our study may be related to the indolent natural history of their disease and the higher activity of cabozantinib in this population. 19 However, because of the small number of patients treated, we cannot support a report of any predictive clinical factors of response.
In the current analysis, cabozantinib treatment was well tolerated, with most patients receiving full doses. Only 5 patients (5%) discontinued treatment because of toxicity. Tolerability in the MAP was better than what was observed in clinical trials, with AEs reported in 93% of patients in the MAP and 100% in the phase 3 clinical trial, respectively. 9, 10 A lower rate of grade 3/4 AEs was observed (36% in MAP vs. 68% in the phase 3 study). This may be related to the smaller sample size and to the possible bias due to the study's retrospective nature; the improved management of both drug dose and AEs, which frequently resolved quickly and effectively with specific treatment or delayed administration, could be explained by a better comprehension of drug activity, interactions, and drug-related events. 20 Our data might modify the prevailing thought that cabozantinib is a highly toxic treatment.
In both the MAP and the clinical trials, diarrhea, fatigue, mucosal inflammation, hypertension, and skin toxicity were the most commonly reported AEs. Overall, several factors suggest that cabozantinib has an acceptable safety profile, as demonstrated by the absence of drug-related deaths and the lack of new or unexpected toxicities. Moreover, feasibility was reported in a large population excluded from the randomized phase 3 clinical trial. Thus, even in a special population of elderly patients with poor clinical conditions and with multiple unfavorable sites of disease, cabozantinib was feasible and manageable. The main limitations of this analysis are the limited number of patients included and the lack of a central radiologic review. Despite these limitations, to our knowledge, this is the first evaluation of the efficacy and safety of cabozantinib in real-life patients with mRCC rather than patients selected for clinical trials. 
Conclusion
Cabozantinib was effective in everyday clinical practice in a large unselected population of mRCC patients who experience disease progression after prior treatment. Cabozantinib was also safe, and its toxicity profile was feasible and manageable.
Clinical Practice Points
The randomized phase 3 METEOR study confirmed a survival benefit with treatment of cabozantinib over everolimus in patients with mRCC who experienced disease progression after receipt of at least one previous antiangiogenic inhibitor. Data were collected from 24 Italian cancer centers where a cabozantinib MAP was available, upon physician request, between September and December 2016. Our data showed that cabozantinib was effective in a large unselected population in everyday clinical practice of mRCC patients who experienced disease progression after receipt of prior treatment. Cabozantinib was safe and had a feasible and manageable toxicity profile.
